Diagnostic method for chronic myeloproliferative diseases – method for quantitatively analyzing the JAK2 genetic mutation –

2011-0915-02
researcher's name
affiliation
research field
Biofunction/Bioprocess,Environmental engineering and reduction of environmental burden,Applied microbiology,Bacteriology (including mycology)
keyword

background

Chronic myeloproliferative diseases (cMPD) are conditions in which an abnormality at the hematopoietic level is recognized, which includes polycythemia vera, essential thrombocytosis and primary myelofibrosis. In recent years, a genetic mutation known as Janus kinase 2 (JAK2) has been frequently observed in these conditions.

summary

We have a method of quantitatively analyzing the JAK2 genetic mutation. Using a fluorescent probe, it is possible to diagnose cMPD quickly and accurately.

application/development

●It is a cMPD diagnostic tool that can accurately diagnose polycythemia vera, essential thrombocytosis and primary myelofibrosis.
●It can also be used as a tool for monitoring disease progress and treatment results.

predominance

High-sensitivity qualitative and quantitative measurement: false positives do not readily occur in clinical specimens, with the lowest limit in the quantitative determination of Allele Burden of ~5%. Homo- and heterozygous-type distinction is possible: it can accurately diagnose cMPD. Low cost, simple operation: it is possible to diagnose cMPD in one reaction by fluorescent measurement alone. High throughput: 96 – 384 samples can be measured simultaneously, and assay results obtained in two to three hours. Test samples: blood, bone, spinal fluid, etc.

purpose of providing seeds

Sponsord research, Collaboration research, Technical consultation

material

posted: 2014/05/21